Product Description
Arhalofenate is also purported to have antiinflammatory activity through inhibition of interleukin-1beta (IL-1beta), as demonstrated in a monosodium urate murine air pouch model. Arhalofenate was first developed as an insulin sensitizer for type 2 diabetes mellitus. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982369/)
Mechanisms of Action: URAT1 Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 2: Gout|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CB102-21425 | P2 |
Completed |
Gout |
2015-01-01 |
2019-03-20 |
Treatments |
|
| CB102-21426 | P2 |
Completed |
Gout |
2014-12-01 |
2019-03-20 |
Treatments |
|
| M102-21123 | P2 |
Completed |
Gout |
2012-02-01 |
2019-03-19 |
Treatments |
|
| M102-21122 | P2 |
Completed |
Gout |
2011-11-01 |
2024-06-26 |
Primary Endpoints|Treatments |
|
| M102-21124 | P2 |
Completed |
Gout |
2011-10-01 |
2019-03-19 |
Treatments |
|
| M102-20814 | P2 |
Terminated |
Type 2 Diabetes |
2010-02-01 |
2019-03-18 |
Treatments |
|
| M102-20509 | P3 |
Completed |
Type 2 Diabetes |
2007-11-01 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/01/2024 |
PubMed |
Pipeline Therapies for Gout. |
|
12/01/2023 |
PubMed |
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout. |
|
03/01/2022 |
PubMed |
What's new on the front-line of gout pharmacotherapy? |
|
06/03/2019 |
News Article |
Gout Therapeutic Market is projected to reach US$ 3820 Million by 2027- TMR |